Singlera Genomics signed a research and distribution agreement with Pure Medical to commercialize its mTitan and mGuard cell‑free DNA (cfDNA) methylation sequencing assays across several European countries. The deal covers joint research with universities, hospital networks and national health systems and positions Singlera to expand its early cancer detection footprint in western Europe. Singlera’s patented methylation sequencing platform screens circulating cfDNA for cancer‑associated methylation haplotypes across multiple tumor types, including colorectal, lung and pancreatic cancers. The company said the collaboration supports its European business strategy to lower costs and increase access to non‑invasive cancer screening and monitoring. Financial terms were not disclosed.